Summary of COVID-19 pacritinib studies

1. Cafardi et al., Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19

200 patient pacritinib late treatment RCT: 28% higher mortality (p=0.63), 25% lower progression (p=0.38), and 17% worse improvement (p=0.53).
RCT 200 hospitalized patients with severe COVID-19 showing no significant differences with pacritinib.
Dec 2022, JAMA Network Open, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799198, https://c19p.org/cafardi